ロード中...
Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease
BACKGROUND: Fingolimod is the first oral immunomodulatory therapy approved for highly active relapsing remitting multiple sclerosis. Based on the distribution pattern of fingolimod interacting sphingosine-1-phosphat receptors in organism including immune system and cardiovascular system clinical mon...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4055797/ https://ncbi.nlm.nih.gov/pubmed/24906818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-14-126 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|